Why is the Paradigm share price surging 7% today?

The biopharmaceutical company is partnering with the National Football League's Alumni Health service.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Paradigm shares lift more than 7% to $1.125 on Wednesday
  • The company entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA)
  • NFL Alumni Health will pass on information about Paradigm’s role in developing a treatment for pain and dysfunction associated with knee osteoarthritis

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is in the green on Wednesday following the company's latest announcement.

At the time of writing, the biopharmaceutical company's shares are fetching at $1.055 each, up 0.48%. Earlier in the session, the company's share price hit $1.125, a surge of more than 7%.

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.

Image source: Getty Images

What did Paradigm announce?

According to this morning's announcement, Paradigm advised that it has entered into a corporate partnership with the US's National Football League Alumni Health (NFLAH).

Under the collaboration, NFL Alumni Association (NFLAA) members will be informed about osteoarthritis (OA) and current treatment options. Furthermore, information will be provided to interested participants about actively enrolling in OA clinical trials throughout the United States.

The NFL's Alumni Association has more than 10,000 members which consist of former NFL players, coaches, executives, spouses, cheerleaders, and associate members.

Paradigm is seeking to unlock the potential benefits of pentosan polysulfate sodium (PPS) for the treatment of musculoskeletal disorders.

Paradigm's leading drug candidate Zilosul is used to treat OA, a progressive disease that affects more than 240 million people globally.

The injectable PPS treatment has previously shown improvements in pain reduction, joint function, and the prevention of cartilage damaging joints.

It seems investors are excited about the company expanding its access program for the potential treatment of OA, sending the Paradigm share price higher.

Paradigm CEO Marco Polizzi commented:

Having followed the progress of the expanded access program participants and hearing first-hand the positive impact Zilosul has had on their lives, Paradigm is honoured to be able to continue to work with NFL Alumni members to inform them of the onset and progression of osteoarthritis and Paradigm's clinical progress through phase 3 as we strive to bring Zilosul to commercialisation for the millions suffering from the debilitating effects of OA.

About the Paradigm share price

The Paradigm share price is down 48% in the past 12 months with most of these losses in the year to date.

The company's shares reached a 52-week low of 85.5 cents a share in late June before rebounding over the past two weeks.

Based on the current share price, Paradigm has a market capitalisation of around $236 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »